Pros And Cons Of Roll Compaction - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pros And Cons Of Roll Compaction


Pharmaceutical Technology Europe
Volume 23, Issue 3

There are two types of widely used dry granulation methods: slugging and roll compaction. Currently, roll compaction is preferred to slugging because it offers greater capacity and ease of process control. It also offers a higher manufacturing efficiency per hour and is a continuous process unlike slugging, which is a batch process.


Imjak Jeon. Regulatory Affairs Manager at Crucell Switzerland AG.
Dry granulation methods are especially suitable for moisture- and/or heat-sensitive compounds because no liquid or drying steps are required. They can also be used for substances possessing poor flowability and compaction behaviour, such as acetaminophen and ibuprofen. Roll compaction, in particular, is also highly suitable for hygroscopic materials such as dry herbal extract.

Compared with wet granulation, dry granulation by roll compaction is a simpler, continuous process. In wet granulation, granules are produced according to the following steps: mixing, preparation of binder solution, granulation and drying. In dry granulation, the procedure is shorter because preparation of binder solution and drying are not required. In dry granulation, the steps are: mixing, roll compaction and milling, which requires less equipment, time and energy.

Room for improvement

One of the disadvantages of roll compaction, however, is a phenomenon called ‘loss of reworkability’. Tablets made by roll compaction often show inferior tensile strength compared to tablets prepared by wet granulation or direct compaction. Because this phenomenon is more profound in plastic substances, adjusting the plastic/brittle balances of starting materials by selecting appropriate excipients is much more. Also, minimum compaction force should be used, as well as a smaller particle size of starting powder.

A second disadvantage of roll compaction is the production of non‑compacted powder. Because no liquid binder is used, high amounts of fines remain and less product yield is obtained versus wet granulation.

More information about overcoming loss of reworkability and minimising the limitations of roll compaction can be read at http://www.pharmtech.com/jeon

Roll compaction is a simple dry granulation method, but there are many factors that must be considered, controlled and optimised, for example, roll pressure, roll speed and the feeding rate of starting materials. These factors determine the product properties (e.g., ribbons, granules, etc.), as well as the final tablets. Important product quality such as the density of ribbons, flowability, compressibility and tabletting ability of granules, as well as the tensile strength of the finished tablets, are highly dependent on the parameters mentioned above.

Controlling these factors is important to achieve a product of desired quality. A full understanding of the chemical and physical properties of the starting materials and the process parameters is also essential. To improve roll compaction, I believe that good modelling according to the type of machine used and the characteristics of starting materials would be very helpful to predict, control and optimise the process, as well as improve product quality.

This article is part of a special feature on granulation that was published in the March issue of PTE Digital, available at http://www.pharmtech.com/ptedigital0311

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here